HTN was reported to be independently associated with increased risk of both VEGF-related adverse vascular events (AVEs) and discontinuation due to VEGF-related AVEs, which may be an important factor to affect the prognosis of immunotherapy (52). This evidence concerns the gene VEGFA and hypertensive disorder.